TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Elekta AB ( ($SE:EKTA.B) ) is now available.
Elekta has released its ‘2025 Impact Report’ emphasizing the importance of radiotherapy in modern cancer care. The report advocates for broader adoption and access to advanced radiotherapy, highlighting innovations like adaptive radiotherapy that improve precision and patient outcomes. The report also serves as a resource for cancer patients, showcasing the role of radiotherapy as both a standalone and complementary treatment, and includes patient testimonials demonstrating the benefits of advanced technologies.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a leader in precision radiation therapy, dedicated to providing access to advanced cancer care. The company collaborates with customers to develop sustainable, outcome-driven, and cost-efficient solutions. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 1,081,893
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.67B
See more insights into EKTA.B stock on TipRanks’ Stock Analysis page.